Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of plitidepsin versus control in hospitalized adults with moderate COVID-19
2020-005951-19Phase 3Completed
- Sponsor
- PharmaMar
- Start
- Apr 2021
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of plitidepsin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by PharmaMar. Primary endpoint: Complete recovery by Day 8. Started Apr 2021; status: completed.
02
Drugs
plitidepsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005951-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005951-19.